Anti-RSV (Felvizumab Biosimilar)
Catalog #500029
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500029 | 1 mg | $250.00 | ||
| 500029 | 5 mg | $750.00 | ||
| 500029 | 20 mg | $2,000.00 |
Product Details
Felvizumab is a humanized monoclonal antibody designed to target the Respiratory Syncytial Virus (RSV), which is responsible for respiratory infections, particularly in young children and the elderly. It works by binding to the F protein of RSV, which plays a critical role in the virus's ability to infect cells. Felvizumab is often classified as a biosimilar, meaning it is a version of a previously approved antibody with highly similar properties, developed for research and therapeutic purposes​
Specifications
| Clone | Felvizumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | RSV |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |